The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Open accessAbstract
BACKGROUND: Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer. METHODS: We randomly assigned patients with stage IIIC or IV epithelial ovarian carcinoma, fallopian-tube carcinoma, or primary peritoneal carcinoma to primary debulking surgery followed by platinum-based chemotherapy or to neoadjuvant platinum-based chemotherapy followed by debulking surgery (so-called interval debulking surgery). RESULTS: Of the 670 patients randomly assigned to a study treatment, 632 (94.3%) were eligible and started the treatment. The majority of these patients had extensive stage IIIC or IV disease at primary debulking surgery (metastatic lesions that were larger than 5 cm in diameter in 74.5% of patients and larger than 10 cm in 61.6%). The largest residual tumor was 1 cm or less in diameter in 41.6% of patients after primary debulking and in 80.6% of patients after interval debulking. Postoperative rates of adverse effects and mortality tended to be higher after primary debulking than after interval debulking. The hazard ratio for death (intention-to-treat analysis) in the group assigned to neoadjuvant chemotherapy followed by interval debulking, as compared with the group assigned to primary debulking surgery followed by chemotherapy, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P=0.01 for noninferiority), and the hazard ratio for progressive disease was 1.01 (90% CI, 0.89 to 1.15). Complete resection of all macroscopic disease (at primary or interval surgery) was the strongest independent variable in predicting overall survival. CONCLUSIONS: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study. Complete resection of all macroscopic disease, whether performed as primary treatment or after neoadjuvant chemotherapy, remains the objective whenever cytoreductive surgery is performed. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00003636.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
HEINTZ, A., ODICINO, F., MAISONNEUVE, P., QUINN, M., BENEDET, J., CREASMAN, W., NGAN, H., PECORELLI, S., & BELLER, U. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60033-7 · Cited by 1,277
Self-citationvan der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321002 · Cited by 705
Self-citationChi, D. S., Eisenhauer, E. L., Lang, J., Huh, J., Haddad, L., Abu-Rustum, N. R., Sonoda, Y., Levine, D. A., Hensley, M., & Barakat, R. R. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.051 · Cited by 634
van der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199507000-00012 · Cited by 578
Self-citationEisenkop, S. M., Friedman, R. L., & Wang, H.-J. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.4955 · Cited by 507
du Bois, A., Quinn, M., Thigpen, T., Vermorken, J., Avall-Lundqvist, E., Bookman, M., Bowtell, D., Brady, M., Casado, A., Cervantes, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi961 · Cited by 465
Self-citationVergote, I., De Wever, I., Tjalma, W., Van Gramberen, M., Decloedt, J., & van Dam, P. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5213 · Cited by 382
Self-citationRe: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Rustin, G. J. S., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I., et al. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh081 · Cited by 378
Self-citationClinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases.
Aure, J. C., Høeg, K., & Kolstad, P. (1971) · PubMed · Cited by 253
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
Vergote, I. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1534 · Cited by 239
Self-citationCrawford, S. C., Vasey, P. A., Paul, J., Hay, A., Davis, J. A., & Kaye, S. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1287 · Cited by 198
Intensive Surgical and Chemotherapeutic Management of Advanced Ovarian Cancer
Griffiths, C. T., & Fuller, A. F. (1978) · Surgical Clinics of North America · doi:10.1016/s0039-6109(16)41440-4 · Cited by 188
Kang, S., & Nam, B.-H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0558-6 · Cited by 178
Schrag, D., Earle, C., Xu, F., Panageas, K. S., Yabroff, K. R., Bristow, R. E., Trimble, E. L., & Warren, J. L. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj018 · Cited by 170
Port-site metastases after open laparoscopy: A study in 173 patients with advanced ovarian carcinoma
Vergote, I., Marquette, S., Amant, F., Berteloot, P., & Neven, P. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00135.x · Cited by 133
Self-citationRisum, S., Høgdall, C. K., Loft, A., Berthelsen, A. K., Høgdall, E. V. S., Nedergaard, L., Lundvall, L., & Engelholm, S. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.002 · Cited by 105
Specialized Care and Survival of Ovarian Cancer Patients in The Netherlands: Nationwide Cohort Study
Vernooij, F., Heintz, A. P. M., Witteveen, P. O., der Loo, M. V. D. H., Coebergh, J. W. W., & van der Graaf, Y. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn033 · Cited by 92
Timing of debulking surgery in advanced ovarian cancer
Vergote, I. B., Gorp, T. V., Amant, F. C., Leunen, K., Neven, P., & Berteloot, P. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01098.x · Cited by 88
Self-citationSurvival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study
O’Malley, C. D., Cress, R. D., Campleman, S. L., & Leiserowitz, G. S. (2003) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.08.010 · Cited by 81
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Metadata
- Authors
- Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G. C. E., Pecorelli, S., & Reed, N. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 943-953
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2106767659
- Cited by
- 2,537
- References
- 22
- FWCI
- 124.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.